Showing results (161-170 of 432) with videos related to

Sort By:
Pageof 44
Cancers|June 12, 2026
Surgical Approach to Liver Metastasis from Gastroenteropancreatic Neuroendocrine Tumors in the Era of Precision OncologyJorgelina Coppa, Simone Oldani, Sara Pusceddu, et al.
Expert Review of Anticancer Therapy|June 30, 2016
Update on medical treatment of small intestinal neuroendocrine tumorsSara Pusceddu, Daniela Femia, Giuseppe Lo Russo, et al.
Tumori|August 18, 2021
Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effectsValentina Fuoco, Giovanni Argiroffi, Stefania Mazzaglia, et al.
Tumori|March 3, 2020
Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei TumoriAlessandra Raimondi, Pierangela Sepe, Melanie Claps, et al.
Cancer|April 23, 2014
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group studyEmilio Bajetta, Laura Catena, Nicola Fazio, et al.
Current Oncology Reports|March 31, 2023
Current Status of Predictive Biomarker Development in Metastatic Renal Cell CarcinomaGiuseppe Fotia, Marco Stellato, Valentina Guadalupi, et al.
JAMA Oncology|April 14, 2022
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)Giuseppe Procopio, Pierangela Sepe, Melanie Claps, et al.
Japanese Journal of Clinical Oncology|November 19, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' studyAlessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, et al.
International Journal of Molecular Sciences|February 27, 2020
Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to ProgressionVera Cappelletti, Elena Verzoni, Raffaele Ratta, et al.
Scientific Reports|October 1, 2021
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRTFederica Scalorbi, Giovanni Argiroffi, Michela Baccini, et al.
Pageof 44